Can DIO2 rs225014 reduce local T4-to-T3 activation and shift thyroid markers?

The DIO2 rs225014 (Thr92Ala) polymorphism is a genetic variant that impacts the local tissue-level activation of thyroxine (T4) to the active triiodothyronine (T3).

Mechanistic pathways

• Enzyme instability and degradation: The Thr92Ala substitution causes structural alterations that enhance the enzyme's susceptibility to substrate-induced ubiquitination, rapid proteasomal degradation, and endoplasmic reticulum (ER)/Golgi stress.
• Reduced catalytic capacity: Rather than altering substrate binding affinity ($K_m$), this accelerated degradation lowers the effective concentration and maximal catalytic velocity ($V_{max}$) of the type 2 deiodinase (D2) enzyme in target tissues.

Clinical and hormonal profile

• Intracellular T3 deficit: Impaired D2 activity reduces local intracellular T4-to-T3 conversion, particularly in D2-dependent tissues like skeletal muscle, the brain, and the pituitary. This leads to a thyroid hormone profile of below-optimal free T3 (FT3) with preserved or above-optimal free T4 (FT4).
• Compensatory TSH elevation: Because pituitary negative feedback depends on local T4-to-T3 conversion via D2, an intracellular T3 deficit in pituitary cells limits feedback inhibition, provoking compensatory elevations in thyroid-stimulating hormone (TSH).
• Normal reverse T3: Reverse T3 (rT3) is generated by type 3 deiodinase (D3) and cleared by type 1 deiodinase (D1). Because D2 does not generate rT3, this discordant thyroid profile (high FT4, low FT3, and elevated TSH) occurs without any elevation in circulating rT3 levels.

Bottom line

• The DIO2 rs225014 polymorphism causes functional D2 impairment via post-translational degradation and cellular stress. This provides a clear biological explanation for a thyroid profile of above-optimal FT4, below-optimal FT3, and elevated TSH, occurring independently of elevated reverse T3.